New drug shows promise against ovarian and breast cancer
August 13th, 2010 - 4:09 pm ICT by ANILondon, Aug 13 (ANI): An international consortium of researchers has shown that an investigational drug, Olaparib, can reduce the size of tumors in women with advanced hereditary ovarian cancer with BRCA gene mutations.
The Phase II ovarian cancer study results - as well as another Phase II trial in which Cedars-Sinai researchers also participated that evaluated the drug’s effectiveness in the treatment of hereditary breast cancer - were published in a recent issue of Lancet.
The two trials showed similar levels of response to the genetically-targeted drug in both breast and ovarian cancers with BRCA mutations.
“These are significant new studies. Olaparib is the first single-agent, non-chemotherapy treatment to show benefit to patients with cancers that result from BRCA1 or BRCA2 gene mutations,” said William Audeh, M.D., an oncologist specializing in cancer genetics at Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute and first author on the ovarian cancer study
“Until now, treatments for cancer have been selected based upon where in the body the cancer originated. These two studies suggest that it is the underlying genetic weakness of a cancer, not the organ of origin, that is the key to selecting effective therapy.” (ANI)
- Revolutionary therapy shows promise for breast cancer patients: Lancet - Jul 06, 2010
- Wonder drug could kill all types of cancer - Jun 27, 2011
- New ovarian and breast cancer treatments - Feb 23, 2010
- New drug shows promise against platinum resistant ovarian cancer - Oct 10, 2010
- Genes linked to hereditary breast and ovary cancer identified - Feb 19, 2011
- New genetic marker of ovarian cancer risk discovered - Jul 21, 2010
- Genetic variants that modify breast cancer risk identified - Sep 20, 2010
- Study finds new risk factor for developing breast cancer - Nov 11, 2010
- 'Smart' new drug shows promise in ovarian cancer - Nov 09, 2010
- 'Space Age' cancer drug shows promise - Jun 25, 2009
- Genetic variants may affect breast cancer risk in women with BRCA2 mutations - Oct 29, 2010
- New 'nanodrug' can attack breast cancer cells from the inside out - Mar 30, 2011
- New breast and ovarian cancer susceptibility gene identified - Apr 22, 2010
- New genetic links to ovarian cancer risk discovered - Sep 20, 2010
- Faulty gene spikes prostate cancer risk in men - Apr 22, 2012
Tags: brca mutations, brca1, brca2 gene, breast cancer, cancer genetics, cancer institute, cancer study, cedars sinai, chemotherapy treatment, effective therapy, gene mutations, genetic weakness, hereditary breast cancer, hereditary ovarian cancer, international consortium, investigational drug, lancet, oncologist, ovarian cancer, ovarian cancers